- Home
- GAN vs ALRN Comparison
GAN vs ALRN Comparison
Compare GAN & ALRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GAN
- ALRN
- Stock Information
- Founded
- GAN 1999
- ALRN 2001
- Country
- GAN United States
- ALRN United States
- Employees
- GAN N/A
- ALRN N/A
- Industry
- GAN Computer Software: Programming Data Processing
- ALRN Biotechnology: Pharmaceutical Preparations
- Sector
- GAN Technology
- ALRN Health Care
- Exchange
- GAN Nasdaq
- ALRN Nasdaq
- Market Cap
- GAN 83.2M
- ALRN 76.9M
- IPO Year
- GAN 2020
- ALRN 2017
- Fundamental
- Price
- GAN $1.84
- ALRN $1.97
- Analyst Decision
- GAN
- ALRN Strong Buy
- Analyst Count
- GAN 0
- ALRN 1
- Target Price
- GAN N/A
- ALRN $19.00
- AVG Volume (30 Days)
- GAN 218.4K
- ALRN 137.2K
- Earning Date
- GAN 03-12-2025
- ALRN 11-14-2024
- Dividend Yield
- GAN N/A
- ALRN N/A
- EPS Growth
- GAN N/A
- ALRN N/A
- EPS
- GAN N/A
- ALRN N/A
- Revenue
- GAN $134,024,000.00
- ALRN N/A
- Revenue This Year
- GAN $5.97
- ALRN N/A
- Revenue Next Year
- GAN $11.32
- ALRN N/A
- P/E Ratio
- GAN N/A
- ALRN N/A
- Revenue Growth
- GAN N/A
- ALRN N/A
- 52 Week Low
- GAN $1.17
- ALRN $1.61
- 52 Week High
- GAN $1.87
- ALRN $7.42
- Technical
- Relative Strength Index (RSI)
- GAN 53.95
- ALRN 41.44
- Support Level
- GAN $1.81
- ALRN $1.90
- Resistance Level
- GAN $1.85
- ALRN $2.17
- Average True Range (ATR)
- GAN 0.02
- ALRN 0.18
- MACD
- GAN 0.00
- ALRN 0.02
- Stochastic Oscillator
- GAN 75.00
- ALRN 23.27
About GAN GAN Limited
GAN Ltd provides Software-as-a-Service solutions for online casino gaming and sports betting applications. The company has two operating segments B2B and B2C. The B2B segment develops, markets, and sells instances of GameSTACK, GAN Sports, and iSight Back Office technology that incorporates comprehensive player registration, account funding, and back-office accounting and management tools that enable the casino operators to efficiently, confidently, and effectively extend their presence online in places that have permitted online real money gaming, and The B2C segment, which includes the operations of Coolbet, develops and operates a B2C online sports betting and casino platform that is accessible through its website in markets across Northern Europe, Latin America, and Canada.
About ALRN Aileron Therapeutics Inc.
Aileron Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53 mutations to reduce or eliminate chemotherapy-induced side effects. The company currently has two product candidates in clinical development, LTI-03 and LTI-01, and multiple candidates in preclinical development focused on fibrosis indications.